NCT05359211 - NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 8, 2022

Primary Completion Date

September 4, 2025

Study Completion Date

September 4, 2026

Conditions

Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular LymphomaRecurrent Primary Mediastinal Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRefractory Grade 3b Follicular LymphomaRefractory Primary Mediastinal Large B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

BIOLOGICAL

Lisocabtagene Maraleucel

Given IV

DRUG

Polymer-conjugated IL-15 Receptor Agonist NKTR-255

Given IV

PROCEDURE

X-Ray Imaging

Undergo x-ray imaging

PROCEDURE

Echocardiography

Undergo ECHO

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy and aspiration

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow biopsy and aspiration

PROCEDURE

Lumbar Puncture

Undergo LP

PROCEDURE

Computed Tomography

Undergo PET/CT

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

PROCEDURE

Biospecimen Collection

Undergo blood and CSF sample collection

PROCEDURE

Biopsy

Undergo tissue biopsy

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle